Chimeric Therapeutics Valuation
| CHM Stock | 0.01 0.0005 11.11% |
Chimeric Therapeutics seems to be fairly valued based on Macroaxis valuation methodology. Our model approximates the value of Chimeric Therapeutics from analyzing the firm fundamentals such as Return On Equity of -1.8, shares outstanding of 2.02 B, and Operating Margin of (0.48) % as well as examining its technical indicators and probability of bankruptcy.
Price Book 1.6963 | Enterprise Value 10.6 M | Enterprise Value Ebitda (2.14) | Price Sales 3.9488 | Enterprise Value Revenue 8.3 K |
Fairly Valued
Today
Please note that Chimeric Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Chimeric Therapeutics is based on 3 months time horizon. Increasing Chimeric Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Chimeric Therapeutics' intrinsic value may or may not be the same as its current market price of 0.01, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.005 | Real 0.004876 | Hype 0.006218 | Naive 0.004413 |
The intrinsic value of Chimeric Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Chimeric Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Chimeric Therapeutics helps investors to forecast how Chimeric stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Chimeric Therapeutics more accurately as focusing exclusively on Chimeric Therapeutics' fundamentals will not take into account other important factors: Chimeric Therapeutics Cash |
|
Chimeric Therapeutics Total Value Analysis
Chimeric Therapeutics is currently expected to have takeover price of 10.62 M with market capitalization of 8.06 M, debt of 3.59 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Chimeric Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.62 M | 8.06 M | 3.59 M |
Chimeric Therapeutics Investor Information
About 19.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.7. Some equities with similar Price to Book (P/B) outperform the market in the long run. Chimeric Therapeutics recorded a loss per share of 0.02. The entity had not issued any dividends in recent years. Based on the key indicators related to Chimeric Therapeutics' liquidity, profitability, solvency, and operating efficiency, Chimeric Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Chimeric Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Chimeric Therapeutics has an asset utilization ratio of 48.83 percent. This implies that the Company is making USD0.49 for each dollar of assets. An increasing asset utilization means that Chimeric Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Chimeric Therapeutics Ownership Allocation
Chimeric Therapeutics holds a total of 2.02 Billion outstanding shares. Chimeric Therapeutics shows 18.54 percent of its outstanding shares held by insiders and 1.07 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Chimeric Therapeutics Profitability Analysis
The company reported the revenue of 7.46 M. Net Loss for the year was (12.53 M) with profit before overhead, payroll, taxes, and interest of 2.04 M.About Chimeric Therapeutics Valuation
The stock valuation mechanism determines Chimeric Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Chimeric Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Chimeric Therapeutics. We calculate exposure to Chimeric Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Chimeric Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 8.6 M | 9 M |
Additional Tools for Chimeric Stock Analysis
When running Chimeric Therapeutics' price analysis, check to measure Chimeric Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chimeric Therapeutics is operating at the current time. Most of Chimeric Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chimeric Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chimeric Therapeutics' price. Additionally, you may evaluate how the addition of Chimeric Therapeutics to your portfolios can decrease your overall portfolio volatility.